United Therapeutics Corporation (NASDAQ:UTHR) Q3 2022 Earnings Conference Call November 2, 2022 9:00 AM ET

Company Participants

Dewey Sedman – Head-Investor Relations

Martine Rothblatt – Chairperson and Chief Executive Officer

Michael Benkowitz – President and Chief Operating Officer

Conference Call Participants

Eun Yang – Jefferies

Hartaj Singh – Oppenheimer & Company

Terence Flynn – Morgan Stanley

Joseph Thome – Cowen and Company

Jessica Fye – JPMorgan

Andreas Argyrides – Wedbush

Operator

Good morning, and welcome to the United Therapeutics Corporation Third Quarter 2022 Earnings Webcast. My name is Chantel and I will be your conference operator today. All participants on the call portion of the webcast will be in a listen-only mode until the question-and-answer portion of this earnings call. [Operator Instructions] I will now turn the webcast over to Dewey Steadman, Head of Investor Relations at United Therapeutics.

Dewey Sedman

Good morning. It’s my pleasure to welcome you to the United Therapeutics Corporation third quarter 2022 earnings webcast. Accompanying me on today’s call are Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer; Michael Benkowitz, our President and Chief Operating Officer; James Edgemond, our Chief Financial Officer and Treasurer; and Pat Poisson, our Executive Vice President of Technical Operations; and Dr. Leigh Peterson, our Senior Vice President of Product Development.

Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including Forms 10-K and 10-Q, contain additional information on these risks and uncertainties. We assume no obligation to update forward-looking statements.

After today’s remarks may discuss the progress and results of clinical trials or other developments with respect to our products. These remarks are intended solely to educate investors and are not intended to serve as the basis for medical decision-making or to suggest that any products are safe and effective for any unapproved or investigational uses. A full prescribing information for these products are available on our website.

Now, I’ll turn the webcast over to Dr. Rothblatt for an overview of the third quarter 2022 financial results and business activities of United Therapeutics. Martine?

Martine Rothblatt

Thanks, Dewey. Good morning, everyone. Currently, we are helping about 12,000 patients, including over 10,000 treprostinil patients, a high mark for our company. And we are making great progress on our goal of 25/25, meaning helping 25,000 patients by the year 2025.